^
Association details:
| Biomarker: | KRAS mutation + EGFR amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study
Excerpt:
FISH analysis of 87 metastatic colorectal cancer patients treated with cetuximab was done...However, in KRAS-mutant patients, a mean EGFR GCN ≥2.83 was related with shorter median progression-free survival (2.8 versus 3.9 months; P = 0.084) and overall survival (3.8 versus 7.5 months; P = 0.006).
DOI:
10.1158/1078-0432.CCR-08-0449
